Literature DB >> 24086863

Determination of Sites Involved, HIV Co-Infection & Utility of Diagnostic Modalities in EPTB.

Aruna Shanmuganathan1, Srinivasan R, Thilagavathy G, Satishkumar D, Sidduraj C, Bonny James.   

Abstract

BACKGROUND: Tuberculosis remains a major global public health problem and an on-going epidemic. Though the chief objectives of the Revised National Tuberculosis Control Programme (RNTCP) in detecting and curing the infectious pulmonary cases is well taken, there has been a steady rise in the number of Extra Pulmonary Tuberculosis (EPTB) cases as documented in several studies. EPTB which usually constitutes around 15%-20% of the total TB cases is now being increasingly reported due to a combination of better diagnostic facilities, and the HIV pandemic. Though several studies have shown increasing prevalence of EPTB, only few studies are available, especially in the Indian scenario, that study the pattern and risk factors. Hence, this retrospective observational study was undertaken to determine the sites of the involvement, HIV co-infection and usefulness of various diagnostic modalities in EPTB affecting patients attending a medical college DOTS clinic.
MATERIAL AND METHODS: One hundred ten EPTB patients referred to the DOTS clinics of the TB & Chest department from the period Dec 2010- Mar 2012 were included in the study. The diagnosis of EPTB was established by combined clinical, microbiological, histopathological &/or imaging modalities. Their medical records were assessed to determine the age distribution, gender and anatomical sites of involvement. The presence of co-morbid conditions like smoking history, alcoholism, diabetic and HIV status were noted. BCG status and Mantoux test readings were recorded. The different diagnostic tests used in confirming EPTB at different sites were recorded. Chest x-ray was analysed for all patients to assess coexisting pulmonary involvement. All patients were followed to assess the outcome of treatment.
RESULTS: The mean age of patients was 34.4. The male to female ratio was 58:52 showing a slight male predominance. The most common site of involvement was lymph node followed by pleural effusion and abdominal TB. The prevalence of lymph node TB was noted to be higher in female patients as compared to other sites of EPTB. Mantoux test was positive in 57 (51.8%) patients. HIV co-infection was noted in only 3 (2.7%) patients. Concomitant pulmonary involvement was seen in 19 (17.3%) patients.
CONCLUSIONS: Lymph node was the most common site involvement showing a significant female preponderance followed by pleural effusion and abdominal TB. The rates of HIV co-infection and diabetes mellitus were 2.7% and 20% respectively. The most useful diagnostic modality was tissue sampling followed by imaging. Mantoux test is not unequivocal for the diagnosis of EPTB.

Entities:  

Keywords:  DOTS clinic; Extra–Pulmonary Tuberculosis; HIV co-infection; Mantoux test; TB Lymphadenopathy

Year:  2013        PMID: 24086863      PMCID: PMC3782920          DOI: 10.7860/JCDR/2013/6363.3301

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  16 in total

1.  Unexpected pulmonary involvement in extrapulmonary tuberculosis patients.

Authors:  Tanyalak Parimon; Christopher E Spitters; Nisa Muangman; Juntima Euathrongchit; Eyal Oren; Masahiro Narita
Journal:  Chest       Date:  2008-07-18       Impact factor: 9.410

Review 2.  HIV-TB co-infection: epidemiology, diagnosis & management.

Authors:  S K Sharma; Alladi Mohan; Tamilarasu Kadhiravan
Journal:  Indian J Med Res       Date:  2005-04       Impact factor: 2.375

Review 3.  Extrapulmonary tuberculosis: an overview.

Authors:  Marjorie P Golden; Holenarasipur R Vikram
Journal:  Am Fam Physician       Date:  2005-11-01       Impact factor: 3.292

4.  Extrapulmonary tuberculosis: a retrospective review of 194 cases at a tertiary care hospital in Karachi, Pakistan.

Authors:  Subhash Chandir; Subash Chandir; Hamidah Hussain; Naseem Salahuddin; Mohammad Amir; Farheen Ali; Ismat Lotia; Amir Javed Khan
Journal:  J Pak Med Assoc       Date:  2010-02       Impact factor: 0.781

5.  Risk of development of tuberculosis in HIV-infected patients.

Authors:  S Swaminathan; R Ramachandran; G Baskaran; C N Paramasivan; U Ramanathan; P Venkatesan; R Prabhakar; M Datta
Journal:  Int J Tuberc Lung Dis       Date:  2000-09       Impact factor: 2.373

6.  Scenario of extrapulmonary tuberculosis in a tertiary care center.

Authors:  R Makaju; A Mohammad; N K Thakur
Journal:  J Nepal Health Res Counc       Date:  2010-04

Review 7.  Extrapulmonary tuberculosis.

Authors:  S K Sharma; A Mohan
Journal:  Indian J Med Res       Date:  2004-10       Impact factor: 2.375

8.  Predictors of pulmonary involvement in patients with extra-pulmonary tuberculosis.

Authors:  Malak M El-Hazmi; Fawzia E Al-Otaibi
Journal:  J Family Community Med       Date:  2012-05

9.  Evaluation of revised national tuberculosis control program, district Kangra, Himachal Pradesh, India, 2007.

Authors:  Surender Nikhil Gupta; Naveen Gupta
Journal:  Lung India       Date:  2011-07

10.  Comparison of pulmonary and extrapulmonary tuberculosis in Nepal- a hospital-based retrospective study.

Authors:  Chandrashekhar T Sreeramareddy; Kishore V Panduru; Sharat C Verma; Hari S Joshi; Michael N Bates
Journal:  BMC Infect Dis       Date:  2008-01-24       Impact factor: 3.090

View more
  2 in total

1.  Spectrum of Tuberculous Infection in Patients Suffering from HIV/AIDS and Its Correlation with CD-4 Counts: A Retrospective Study from Sikkim.

Authors:  Santosh Prasad Kesari; Bina Basnett; Ajay Chettri
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2016-06-10

2.  Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort.

Authors:  Armon Arpagaus; Fabian Christoph Franzeck; George Sikalengo; Robert Ndege; Dorcas Mnzava; Martin Rohacek; Jerry Hella; Klaus Reither; Manuel Battegay; Tracy Renee Glass; Daniel Henry Paris; Farida Bani; Omary Ngome Rajab; Maja Weisser
Journal:  PLoS One       Date:  2020-03-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.